Compile Data Set for Download or QSAR
Report error Found 1562 of affinity data for UniProtKB/TrEMBL: O60502
TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM193647(US9199949, 2)
Affinity DataEC50:  8.80nMT: 2°CAssay Description:The ELISA portion of the assay was performed in a black Maxisorp 96-well plate that was coated overnight at 4° C. with 100 uL/well of the cell ly...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/20/2016
Entry Details
Go to US Patent

TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM193648(US9199949, 4)
Affinity DataEC50:  5.20nMT: 2°CAssay Description:The ELISA portion of the assay was performed in a black Maxisorp 96-well plate that was coated overnight at 4° C. with 100 uL/well of the cell ly...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/20/2016
Entry Details
Go to US Patent

TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM193649(US9199949, 6)
Affinity DataEC50:  5.10nMT: 2°CAssay Description:The ELISA portion of the assay was performed in a black Maxisorp 96-well plate that was coated overnight at 4° C. with 100 uL/well of the cell ly...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/20/2016
Entry Details
Go to US Patent

TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM193650(US9199949, 8)
Affinity DataEC50:  4.70nMT: 2°CAssay Description:The ELISA portion of the assay was performed in a black Maxisorp 96-well plate that was coated overnight at 4° C. with 100 uL/well of the cell ly...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/20/2016
Entry Details
Go to US Patent

TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM50323697(thiamet-G | (3AR,5R,6S,7R,7AR)-2-(ETHYLAMINO)-5-(H...)
Affinity DataEC50:  13nMT: 2°CAssay Description:The ELISA portion of the assay was performed in a black Maxisorp 96-well plate that was coated overnight at 4° C. with 100 uL/well of the cell ly...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2016
Entry Details
Go to US Patent

TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM205418(US9243020, (3aR,5R,6S,7R,7aR)-2-(ethylamino)-5-(hy...)
Affinity DataEC50:  10nMT: 2°CAssay Description:The ELISA portion of the assay was performed in a black Maxisorp 96-well plate that was coated overnight at 4° C. with 100 uL/well of the cell ly...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2016
Entry Details
Go to US Patent

TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM205420(US9243020, 2 | US9815861, Example 2)
Affinity DataEC50:  365nMT: 2°CAssay Description:The ELISA portion of the assay was performed in a black Maxisorp 96-well plate that was coated overnight at 4° C. with 100 uL/well of the cell ly...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2016
Entry Details
Go to US Patent

TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM205421(US9243020, 4 | US9815861, Example 4)
Affinity DataEC50:  358nMT: 2°CAssay Description:The ELISA portion of the assay was performed in a black Maxisorp 96-well plate that was coated overnight at 4° C. with 100 uL/well of the cell ly...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2016
Entry Details
Go to US Patent

TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM205422(US9243020, 9 | US9815861, Example 9)
Affinity DataEC50:  307nMT: 2°CAssay Description:The ELISA portion of the assay was performed in a black Maxisorp 96-well plate that was coated overnight at 4° C. with 100 uL/well of the cell ly...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2016
Entry Details
Go to US Patent

TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM205423(US9243020, 17 | US9815861, Example 17)
Affinity DataEC50:  34nMT: 2°CAssay Description:The ELISA portion of the assay was performed in a black Maxisorp 96-well plate that was coated overnight at 4° C. with 100 uL/well of the cell ly...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2016
Entry Details
Go to US Patent

TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM205424(US9243020, 19 | US9815861, Example 19)
Affinity DataEC50:  53nMT: 2°CAssay Description:The ELISA portion of the assay was performed in a black Maxisorp 96-well plate that was coated overnight at 4° C. with 100 uL/well of the cell ly...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2016
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM205425(US9243020, 20 | US9815861, Example 20)
Affinity DataEC50:  6nMT: 2°CAssay Description:The ELISA portion of the assay was performed in a black Maxisorp 96-well plate that was coated overnight at 4° C. with 100 uL/well of the cell ly...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2016
Entry Details
Go to US Patent

TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM240644(US9409924, (3aR,5R,6R,7S,7aR)-2-(ethylamino)-7-flu...)
Affinity DataEC50:  13nMAssay Description:Inhibition of O-GlcNAcase, which removes O-GlcNAc from cellular proteins, results in an increase in the level of O-GlcNAcylated protein in cells. An ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2017
Entry Details
Go to US Patent

TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM240645(US9409924, (3aR,5R,6R,7S,7aR)-2-(dimethylamino)-7-...)
Affinity DataEC50:  10nMAssay Description:Inhibition of O-GlcNAcase, which removes O-GlcNAc from cellular proteins, results in an increase in the level of O-GlcNAcylated protein in cells. An ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2017
Entry Details
Go to US Patent

TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM240646(US9409924, 1)
Affinity DataEC50:  13nMAssay Description:Inhibition of O-GlcNAcase, which removes O-GlcNAc from cellular proteins, results in an increase in the level of O-GlcNAcylated protein in cells. An ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2017
Entry Details
Go to US Patent

TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM240650(US9409924, 9)
Affinity DataEC50:  74nMAssay Description:Inhibition of O-GlcNAcase, which removes O-GlcNAc from cellular proteins, results in an increase in the level of O-GlcNAcylated protein in cells. An ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2017
Entry Details
Go to US Patent

TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM240654(US9409924, 20)
Affinity DataEC50:  50nMAssay Description:Inhibition of O-GlcNAcase, which removes O-GlcNAc from cellular proteins, results in an increase in the level of O-GlcNAcylated protein in cells. An ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2017
Entry Details
Go to US Patent

TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM240657(US9409924, 34)
Affinity DataEC50:  5.20nMAssay Description:Inhibition of O-GlcNAcase, which removes O-GlcNAc from cellular proteins, results in an increase in the level of O-GlcNAcylated protein in cells. An ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2017
Entry Details
Go to US Patent

TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM240659(US9409924, 38)
Affinity DataEC50:  9.10nMAssay Description:Inhibition of O-GlcNAcase, which removes O-GlcNAc from cellular proteins, results in an increase in the level of O-GlcNAcylated protein in cells. An ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/31/2017
Entry Details
Go to US Patent

TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM50323697(thiamet-G | (3AR,5R,6S,7R,7AR)-2-(ETHYLAMINO)-5-(H...)
Affinity DataEC50:  13nMT: 2°CAssay Description:The ELISA portion of the assay is performed in a black Maxisorp 96-well plate that is coated overnight at 4° C. with 100 uL/well of the cell lysa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2018
Entry Details
Go to US Patent

TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM70885(US9695197, 2)
Affinity DataEC50:  139nMT: 2°CAssay Description:The ELISA portion of the assay is performed in a black Maxisorp 96-well plate that is coated overnight at 4° C. with 100 uL/well of the cell lysa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2018
Entry Details
Go to US Patent

TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM77047(US9695197, 3)
Affinity DataEC50:  29nMT: 2°CAssay Description:The ELISA portion of the assay is performed in a black Maxisorp 96-well plate that is coated overnight at 4° C. with 100 uL/well of the cell lysa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2018
Entry Details
Go to US Patent

TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM77064(US9695197, 4)
Affinity DataEC50:  3nMT: 2°CAssay Description:The ELISA portion of the assay is performed in a black Maxisorp 96-well plate that is coated overnight at 4° C. with 100 uL/well of the cell lysa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2018
Entry Details
Go to US Patent

TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM77863(US9695197, 5)
Affinity DataEC50:  349nMT: 2°CAssay Description:The ELISA portion of the assay is performed in a black Maxisorp 96-well plate that is coated overnight at 4° C. with 100 uL/well of the cell lysa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2018
Entry Details
Go to US Patent

TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM50323697(thiamet-G | (3AR,5R,6S,7R,7AR)-2-(ETHYLAMINO)-5-(H...)
Affinity DataEC50:  21nMAssay Description:Inhibition of OGA (unknown origin) by cell based assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM50557164(CHEMBL4778870)
Affinity DataEC50:  450nMAssay Description:Inhibition of OGA in human SH-SY5Y cells assessed as increase in O-GIcNAcylated protein levels incubated for 48 hrs by in-cell Western assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2022
Entry Details Article
PubMed
TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM50592032(CHEMBL5194370 | US20240018135, Code C-8)
Affinity DataIC50: 0nMAssay Description:Human OGA (recombinant hOGA protein, advanced Protein Technologies corp., Korea) enzyme reaction was performed in a reaction solution containing 25 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM458383(1-(2-(((3R,5S)-1-((6-fluoro-2-methylbenzo[d]thiazo...)
Affinity DataIC50: 0.214nMAssay Description:The OGA enzyme catalyses the removal of O-GlcNAc from nucleocytoplasmic proteins. To measure this activity Fluorescein di-N-acetyl-β-N-acetyl-D-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/11/2021
Entry Details
Go to US Patent

TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM458383(1-(2-(((3R,5S)-1-((6-fluoro-2-methylbenzo[d]thiazo...)
Affinity DataIC50: 0.214nMAssay Description:The OGA enzyme catalyses the removal of O-GlcNAc from nucleocytoplasmic proteins. To measure this activity Fluorescein di-N-acetyl-β-N-acetyl-D-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
Go to US Patent

TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM458383(1-(2-(((3R,5S)-1-((6-fluoro-2-methylbenzo[d]thiazo...)
Affinity DataIC50: 0.214nMAssay Description:Inhibition of full-length human N-terminal poly-His tagged OGA expressed in baculovirus infected Sf9 cells using FD-GlcNAc as substrate preincubated ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2022
Entry Details Article
PubMed
TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM458387(1-[2-[(3R,5S)-1-[(1S)-1-(6-fluoro-2-methyl-1,3-ben...)
Affinity DataIC50: 0.385nMAssay Description:The OGA enzyme catalyses the removal of O-GlcNAc from nucleocytoplasmic proteins. To measure this activity Fluorescein di-N-acetyl-β-N-acetyl-D-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/11/2021
Entry Details
Go to US Patent

TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM458387(1-[2-[(3R,5S)-1-[(1S)-1-(6-fluoro-2-methyl-1,3-ben...)
Affinity DataIC50: 0.385nMAssay Description:The OGA enzyme catalyses the removal of O-GlcNAc from nucleocytoplasmic proteins. To measure this activity Fluorescein di-N-acetyl-β-N-acetyl-D-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
Go to US Patent

TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM458387(1-[2-[(3R,5S)-1-[(1S)-1-(6-fluoro-2-methyl-1,3-ben...)
Affinity DataIC50: 0.385nMAssay Description:Inhibition of full-length human N-terminal poly-His tagged OGA expressed in baculovirus infected Sf9 cells using FD-GlcNAc as substrate preincubated ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2022
Entry Details Article
PubMed
TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM50323697(thiamet-G | (3AR,5R,6S,7R,7AR)-2-(ETHYLAMINO)-5-(H...)
Affinity DataIC50: 0.410nMAssay Description:Inhibition of human O-GlcNAcaseMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/19/2021
Entry Details Article
PubMed
TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM458382(1-(2-(((3R,5S)-1-((6-fluoro-2-methylbenzo[d]thiazo...)
Affinity DataIC50: 0.465nMAssay Description:The OGA enzyme catalyses the removal of O-GlcNAc from nucleocytoplasmic proteins. To measure this activity Fluorescein di-N-acetyl-β-N-acetyl-D-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/11/2021
Entry Details
Go to US Patent

TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM458382(1-(2-(((3R,5S)-1-((6-fluoro-2-methylbenzo[d]thiazo...)
Affinity DataIC50: 0.465nMAssay Description:The OGA enzyme catalyses the removal of O-GlcNAc from nucleocytoplasmic proteins. To measure this activity Fluorescein di-N-acetyl-β-N-acetyl-D-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
Go to US Patent

TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM458382(1-(2-(((3R,5S)-1-((6-fluoro-2-methylbenzo[d]thiazo...)
Affinity DataIC50: 0.465nMAssay Description:Inhibition of full-length human N-terminal poly-His tagged OGA expressed in baculovirus infected Sf9 cells using FD-GlcNAc as substrate preincubated ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2022
Entry Details Article
PubMed
TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM458386(1-[2-[(3R,5S)-1-[(1S)-1-(6-fluoro-2-methyl-1,3-ben...)
Affinity DataIC50: 0.495nMAssay Description:The OGA enzyme catalyses the removal of O-GlcNAc from nucleocytoplasmic proteins. To measure this activity Fluorescein di-N-acetyl-β-N-acetyl-D-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/11/2021
Entry Details
Go to US Patent

TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM458386(1-[2-[(3R,5S)-1-[(1S)-1-(6-fluoro-2-methyl-1,3-ben...)
Affinity DataIC50: 0.495nMAssay Description:The OGA enzyme catalyses the removal of O-GlcNAc from nucleocytoplasmic proteins. To measure this activity Fluorescein di-N-acetyl-β-N-acetyl-D-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
Go to US Patent

TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM458386(1-[2-[(3R,5S)-1-[(1S)-1-(6-fluoro-2-methyl-1,3-ben...)
Affinity DataIC50: 0.495nMAssay Description:Inhibition of full-length human N-terminal poly-His tagged OGA expressed in baculovirus infected Sf9 cells using FD-GlcNAc as substrate preincubated ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2022
Entry Details Article
PubMed
TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM458385(1-[3-[(3R,5S)-1-[(6-fluoro-2-methyl-1,3-benzothiaz...)
Affinity DataIC50: 0.592nMAssay Description:The OGA enzyme catalyses the removal of O-GlcNAc from nucleocytoplasmic proteins. To measure this activity Fluorescein di-N-acetyl-β-N-acetyl-D-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/11/2021
Entry Details
Go to US Patent

TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM458385(1-[3-[(3R,5S)-1-[(6-fluoro-2-methyl-1,3-benzothiaz...)
Affinity DataIC50: 0.592nMAssay Description:The OGA enzyme catalyses the removal of O-GlcNAc from nucleocytoplasmic proteins. To measure this activity Fluorescein di-N-acetyl-β-N-acetyl-D-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
Go to US Patent

TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM458385(1-[3-[(3R,5S)-1-[(6-fluoro-2-methyl-1,3-benzothiaz...)
Affinity DataIC50: 0.592nMAssay Description:Inhibition of full-length human N-terminal poly-His tagged OGA expressed in baculovirus infected Sf9 cells using FD-GlcNAc as substrate preincubated ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2022
Entry Details Article
PubMed
TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM458384(1-[6-[(3R,5S)-1-[(6-fluoro-2-methyl-1,3-benzothiaz...)
Affinity DataIC50: 0.782nMAssay Description:The OGA enzyme catalyses the removal of O-GlcNAc from nucleocytoplasmic proteins. To measure this activity Fluorescein di-N-acetyl-β-N-acetyl-D-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/11/2021
Entry Details
Go to US Patent

TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM458384(1-[6-[(3R,5S)-1-[(6-fluoro-2-methyl-1,3-benzothiaz...)
Affinity DataIC50: 0.782nMAssay Description:The OGA enzyme catalyses the removal of O-GlcNAc from nucleocytoplasmic proteins. To measure this activity Fluorescein di-N-acetyl-β-N-acetyl-D-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
Go to US Patent

TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM458384(1-[6-[(3R,5S)-1-[(6-fluoro-2-methyl-1,3-benzothiaz...)
Affinity DataIC50: 0.782nMAssay Description:Inhibition of full-length human N-terminal poly-His tagged OGA expressed in baculovirus infected Sf9 cells using FD-GlcNAc as substrate preincubated ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2022
Entry Details Article
PubMed
TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM696921(US20240308995, Example 1-1 | US20240308995, Exampl...)
Affinity DataIC50: 1nMAssay Description:Recombinant full length human OGA enzyme was purchased from Origene. 4-MUGlcNAc substrate was purchased from Sigma. All other reagents were purchased...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
Go to US Patent

TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM696931(US20240308995, Example 1-11)
Affinity DataIC50: 1nMAssay Description:Recombinant full length human OGA enzyme was purchased from Origene. 4-MUGlcNAc substrate was purchased from Sigma. All other reagents were purchased...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
Go to US Patent

TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM696932(US20240308995, Example 1-12)
Affinity DataIC50: 1nMAssay Description:Recombinant full length human OGA enzyme was purchased from Origene. 4-MUGlcNAc substrate was purchased from Sigma. All other reagents were purchased...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
Go to US Patent

TargetProtein O-GlcNAcase(Human)
Alectos Therapeutics

US Patent
LigandPNGBDBM696935(US20240308995, Example 1-15)
Affinity DataIC50: 1nMAssay Description:Recombinant full length human OGA enzyme was purchased from Origene. 4-MUGlcNAc substrate was purchased from Sigma. All other reagents were purchased...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
Go to US Patent

Displayed 1 to 50 (of 1562 total ) | Next | Last >>
Jump to: